A cost analysis of long term antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhosis

American Journal of Gastroenterology

Volumn 93, Issue 10, 1998, Pages 1895-1900

  Das, Ananya ^a,b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BILIRUBIN; PROTEIN;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; ASCITES; ASCITES FLUID; BACTERIAL PERITONITIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; HUMAN; LIVER CIRRHOSIS; LONG TERM CARE; MEDICAL DECISION MAKING; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT;

ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DECISION TREES; HOSPITAL CHARGES; HOSPITAL COSTS; HUMANS; LIVER CIRRHOSIS; PERITONITIS; RISK FACTORS; TIME FACTORS;

EID: 0032418778     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1998.00545.x     Document Type: Article

References (25)

1. 1. Rimola A. Infections in liver disease. In: McIntyre N, Benhamou JP, Bircher J, eds. Oxford textbook of clinical hepatology. Oxford: Oxford Medical Press, 1991:1272-84.
2. 2. Runyon BA. Pathogenesis and diagnosis of spontaneous bacterial peritonitis. In: Rodes J, Arroyo V, eds. Therapy in liver diseases. Barcelona: Ediciones DOYMA S.A., 1992:388-96.
3. 3. Rimola A, Bory F, Teres J, et al. Oral non-absorbable antibiotics prevent infections in cirrhosis with gastrointestinal hemorrhage. Hepatology 1985;5:463-7.
4. 4. Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double-blind, placebo-controlled trial. Hepatology 1990;12:716-24.
5. 5. Soriano G, Guarner C, Teixido M, et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991;100:477-81.
6. 6. Rolachon A, Cordier L, Bacq Y, et al. Ciprofloxacin and long term prevention of spontaneous bacterial peritonitis: Results of a prospective controlled trial. Hepatology 1995;22:1171-4.
7. 7. Singh N, Gayoski T, Yu VL, et al. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: A randomized trial. Ann Intern Med 1995;122:595-8.
8. 8. Andreu M, Sola R, Sitges-Serra A, et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993;104:1133-8.
9. 9. Sox HC. Medical decision making. Stoneham, MA: Butterworth-Heinemann, 1988.
10. 10. Finkler SA. The distinction between cost and charge. Ann Intern Med 1982;96:102-9.
11. 11. Younossi ZM, McHutchinson JG, Ganiats TG. An economic analysis of norfloxacin prophylaxis against spontaneous bacterial peritonitis. J Hepatology 1997;27:295-8.
12. 12. The Federal Registrar 1994, Vol. 59, No. 102, Friday, May 27, pp. 27838-9.
13. 13. Doufour MC, Stinson FS. Trends in cirrhosis morbidity and mortality: United States, 1979-88. Semin Liver Dis 1993;13:109-25.
14. 14. Centers for Disease Control and Prevention. Deaths and hospitalizations from chronic liver disease and cirrhosis - United States, 1980-1989. MMWR 1993;41:969-73.
15. 15. Llach J, Rimola A, Miquel N, et al. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: Relevance of ascitic fluid protein concentration. Hepatology 1992;16:724-7.
16. 16. Tito L, Rimola A, Gines P, et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: Frequency and predictive factors. Hepatology 1988;8:27-31.
17. 17. Runyon BA. Spontaneous bacterial peritonitis: An explosion of information. Hepatology 1988;8:171-5.
18. 18. Llovet JM, Bartoli R, Planas R, et al. Bacterial translocation in cirrhotic rats. Its role in the development of spontaneous bacterial peritonitis. Gut 1994;35:1648-52.
19. 19. Runyon BA, Borizo M, Young S, et al. Effect of selective bowel decontamination with norfloxacin on spontaneous bacterial peritonitis, translocation and survival in an animal model of cirrhosis. Hepatology 1995;21:1717-24.
20. 20. Soriano G, Guarner C, Thomas A, et al. Norfloxacin prevents bacterial infection in cirrhosis and gastrointestinal hemorrhage. Gastroenterology 1992;103:1267-72.
21. 21. Inadomi J, Sonnenberg A. Cost-analysis of prophylactic antibiotics in spontaneous bacterial peritonitis. Gastroenterology 1997;113:1289-94.
22. 22. Bow EJ, Rayner E, Louie TJ. Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade off for reduced gram negative sepsis. Am J Med 1988;84:847-54.
23. 23. McEvoy GK. AHFS Drug Information 96. Bethesda: American Society of Health System Pharmacists, 1996:539, 589.
24. 24. Karp JE, Merz WG, Hendriksen C, et al. Oral norfloxacin for prevention of Gram negative bacterial infections in patients with acute leukemia and granulocytopenia: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1987;106:1-7.
25. 25. Johnson PC, Ericsson CD, Morgan DR, et al. Lack of emergence of resistant fecal flora during successful prophylaxis of traveller's diarrhea with norfloxacin. Antimicrob Agents Chemother 1986;3:671-4.